Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty

Nigel Arden, Pascal Richette, Cyrus Cooper, Olivier Bruyère, Eric Abadie, Jaime Branco, Maria Luisa Brandi, Francis Berenbaum, Cécile Clerc, Elaine Dennison, Jean-Pierre Devogelaer, Marc Hochberg, Pieter D'Hooghe, Gabriel Herrero-Beaumont, John A Kanis, Andrea Laslop, Véronique Leblanc, Stefania Maggi, Giuseppe Mautone, Jean-Pierre Pelletier, Florence Petit-Dop, Susanne Reiter-Niesert, René Rizzoli, Lucio Rovati, Eleonora Tajana Messi, Yannis Tsouderos, Johanne Martel-Pelletier, Jean-Yves Reginster, Nigel Arden, Pascal Richette, Cyrus Cooper, Olivier Bruyère, Eric Abadie, Jaime Branco, Maria Luisa Brandi, Francis Berenbaum, Cécile Clerc, Elaine Dennison, Jean-Pierre Devogelaer, Marc Hochberg, Pieter D'Hooghe, Gabriel Herrero-Beaumont, John A Kanis, Andrea Laslop, Véronique Leblanc, Stefania Maggi, Giuseppe Mautone, Jean-Pierre Pelletier, Florence Petit-Dop, Susanne Reiter-Niesert, René Rizzoli, Lucio Rovati, Eleonora Tajana Messi, Yannis Tsouderos, Johanne Martel-Pelletier, Jean-Yves Reginster

Abstract

Osteoarthritis (OA), a disease affecting different patient phenotypes, appears as an optimal candidate for personalized healthcare. The aim of the discussions of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group was to explore the value of markers of different sources in defining different phenotypes of patients with OA. The ESCEO organized a series of meetings to explore the possibility of identifying patients who would most benefit from treatment for OA, on the basis of recent data and expert opinion. In the first meeting, patient phenotypes were identified according to the number of affected joints, biomechanical factors, and the presence of lesions in the subchondral bone. In the second meeting, summarized in the present article, the working group explored other markers involved in OA. Profiles of patients may be defined according to their level of pain, functional limitation, and presence of coexistent chronic conditions including frailty status. A considerable amount of data suggests that magnetic resonance imaging may also assist in delineating different phenotypes of patients with OA. Among multiple biochemical biomarkers identified, none is sufficiently validated and recognized to identify patients who should be treated. Considerable efforts are also being made to identify genetic and epigenetic factors involved in OA, but results are still limited. The many potential biomarkers that could be used as potential stratifiers are promising, but more research is needed to characterize and qualify the existing biomarkers and to identify new candidates.

References

    1. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–293. doi: 10.1038/nrd2251.
    1. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ. 2013;346:e5793. doi: 10.1136/bmj.e5793.
    1. Ethgen O, Reginster JY. Degenerative musculoskeletal disease. Ann Rheum Dis. 2004;63(1):1–3. doi: 10.1136/ard.2003.009613.
    1. Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B, Jonsson H, et al. How to define responders in osteoarthritis. Curr Med Res Opin. 2013;29(6):719–729. doi: 10.1185/03007995.2013.792793.
    1. Hunter DJ, Nevitt M, Losina E, Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res Clin Rheumatol. 2014;28(1):61–71. doi: 10.1016/j.berh.2014.01.007.
    1. Pelletier JP, Cooper C, Peterfy C, Reginster JY, Brandi ML, Bruyere O, et al. What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dis. 2013;72(10):1594–1604. doi: 10.1136/annrheumdis-2013-203631.
    1. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756–1763. doi: 10.1136/annrheumdis-2013-203726.
    1. Bruyere O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015;32(3):179–187. doi: 10.1007/s40266-015-0243-3.
    1. Belo JN, Berger MY, Reijman M, Koes BW, Bierma-Zeinstra SM. Prognostic factors of progression of osteoarthritis of the knee: a systematic review of observational studies. Arthritis Rheum. 2007;57(1):13–26. doi: 10.1002/art.22475.
    1. Lohmander LS, Felson D. Can we identify a ‘high risk’ patient profile to determine who will experience rapid progression of osteoarthritis? Osteoarthr Cartil. 2004;12 Suppl A:S49–S52. doi: 10.1016/j.joca.2003.09.004.
    1. Tanamas S, Hanna FS, Cicuttini FM, Wluka AE, Berry P, Urquhart DM. Does knee malalignment increase the risk of development and progression of knee osteoarthritis? A systematic review. Arthritis Rheum. 2009;61(4):459–467. doi: 10.1002/art.24336.
    1. Leyland KM, Hart DJ, Javaid MK, Judge A, Kiran A, Soni A, et al. The natural history of radiographic knee osteoarthritis: a fourteen-year population-based cohort study. Arthritis Rheum. 2012;64(7):2243–2251. doi: 10.1002/art.34415.
    1. Soni A, Kiran A, Hart DJ, Leyland KM, Goulston L, Cooper C, et al. Prevalence of reported knee pain over twelve years in a community-based cohort. Arthritis Rheum. 2012;64(4):1145–1152. doi: 10.1002/art.33434.
    1. Knoop J, van der Leeden M, Thorstensson CA, Roorda LD, Lems WF, Knol DL, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2011;63(11):1535–1542. doi: 10.1002/acr.20571.
    1. Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa BM, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2014;44(3):253–263. doi: 10.1016/j.semarthrit.2014.05.014.
    1. Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs. 2011;16(3):479–491. doi: 10.1517/14728214.2011.576670.
    1. Lohmander LS, Roos EM. Clinical update: treating osteoarthritis. Lancet. 2007;370(9605):2082–2084. doi: 10.1016/S0140-6736(07)61879-0.
    1. Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68(6):938–947. doi: 10.1136/ard.2008.088732.
    1. Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70(6):982–989. doi: 10.1136/ard.2010.140848.
    1. Pelletier JP, Roubille C, Raynauld JP, Abram F, Dorais M, Delorme P, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis. 2015;74(2):422–429. doi: 10.1136/annrheumdis-2013-203989.
    1. Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(7):1820–1831. doi: 10.1002/art.38614.
    1. Martel-Pelletier J, Roubille C, Abram F, Hochberg MC, Dorais M, Delorme P, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547–556. doi: 10.1136/annrheumdis-2013-203906.
    1. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonte F, Beaudoin G, Bloch DA, et al. Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005;64(4):556–563. doi: 10.1136/ard.2004.023796.
    1. Pelletier JP, Raynauld JP, Berthiaume MJ, Abram F, Choquette D, Haraoui B, et al. Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Res Ther. 2007;9(4):R74. doi: 10.1186/ar2272.
    1. Roubille C, Martel-Pelletier J, Abram F, Dorais M, Delorme P, Raynauld JP, et al. Insight into the role of meniscal extrusion and bone marrow lesions in knee osteoarthritis progression and their impact on response to strontium ranelate treatment in a subset of patients from the SEKOIA study. Ann Rheum Dis. 2014;73(Suppl 2):745. doi: 10.1136/annrheumdis-2014-eular.2539.
    1. Pelletier JP, Roubille C, Abram F, Dorais M, Delorme P, Raynauld JP, et al. The effects of treatment on disease symptoms and progression of structural changes in knee osteoarthritis participants from the osteoarthritis initiative progression cohort. Arthritis Rheum. 2014;66(Suppl 11):S979.
    1. Roubille C, Raynauld JP, Abram F, Paiement P, Dorais M, Delorme P, et al. The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross sectional pilot study. Arthritis Res Ther. 2014;16(6):507–514. doi: 10.1186/s13075-014-0507-z.
    1. Roemer FW, Felson DT, Wang K, Crema MD, Neogi T, Zhang Y, et al. Co-localisation of non-cartilaginous articular pathology increases risk of cartilage loss in the tibiofemoral joint: the MOST study. Ann Rheum Dis. 2013;72(6):942–948. doi: 10.1136/annrheumdis-2012-201810.
    1. Mazzuca SA, Brandt KD, Chakr R, Lane KA. Varus malalignment negates the structure-modifying benefits of doxycycline in obese women with knee osteoarthritis. Osteoarthr Cartil. 2010;18(8):1008–1011. doi: 10.1016/j.joca.2010.03.018.
    1. Conaghan PG, D’Agostino MA, Le BM, Baron G, Schmidely N, Wakefield R, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010;69(4):644–647. doi: 10.1136/ard.2008.099564.
    1. Maricar N, Callaghan MJ, Felson DT. O’neill TW. Predictors of response to intra-articular steroid injections in knee osteoarthritis: a systematic review. Rheumatology (Oxford) 2013;52(6):1022–1032. doi: 10.1093/rheumatology/kes368.
    1. Van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil. 2010;18(5):605–612. doi: 10.1016/j.joca.2010.01.012.
    1. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil. 2006;14(8):723–727. doi: 10.1016/j.joca.2006.04.001.
    1. Spector TD, Cicuttini F, Baker J, Loughlin J, Hart D. Genetic influences on osteoarthritis in women: a twin study. BMJ. 1996;312(7036):940–943. doi: 10.1136/bmj.312.7036.940.
    1. Valdes AM, McWilliams D, Arden NK, Doherty SA, Wheeler M, Muir KR, et al. Involvement of different risk factors in clinically severe large joint osteoarthritis according to the presence of hand interphalangeal nodes. Arthritis Rheum. 2010;62(9):2688–2695. doi: 10.1002/art.27574.
    1. Barter MJ, Young DA. Epigenetic mechanisms and non-coding RNAs in osteoarthritis. Curr Rheumatol Rep. 2013;15(9):353. doi: 10.1007/s11926-013-0353-z.
    1. Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, et al. Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies. Arthritis Rheumatol. 2014;66(4):940–949. doi: 10.1002/art.38300.
    1. Valdes AM, Spector TD, Tamm A, Kisand K, Doherty SA, Dennison EM, et al. Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum. 2010;62(8):2347–2352. doi: 10.1002/art.27530.
    1. Liying J, Yuchun T, Youcheng W, Yingchen W, Chunyu J, Yanling Y, et al. A SMAD3 gene polymorphism is related with osteoarthritis in a Northeast Chinese population. Rheumatol Int. 2013;33(7):1763–1768. doi: 10.1007/s00296-012-2593-z.
    1. Valdes AM, De WG, Doherty SA, Lories RJ, Vaughn FL, Laslett LL, et al. The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis. 2011;70(9):1556–1561. doi: 10.1136/ard.2010.148122.
    1. Neogi T, Soni A, Doherty SA, Laslett LL, Maciewicz RA, Hart DJ, et al. Contribution of the COMT Val158Met variant to symptomatic knee osteoarthritis. Ann Rheum Dis. 2014;73(1):315–317. doi: 10.1136/annrheumdis-2013-203836.
    1. Elliott KS, Chapman K, Day-Williams A, Panoutsopoulou K, Southam L, Lindgren CM, et al. Evaluation of the genetic overlap between osteoarthritis with body mass index and height using genome-wide association scan data. Ann Rheum Dis. 2013;72(6):935–941. doi: 10.1136/annrheumdis-2012-202081.
    1. Kerkhof HJ, Doherty M, Arden NK, Abramson SB, Attur M, Bos SD, et al. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr Cartil. 2011;19(3):265–271. doi: 10.1016/j.joca.2010.12.003.
    1. Raine EV, Dodd AW, Reynard LN, Loughlin J. Allelic expression analysis of the osteoarthritis susceptibility gene COL11A1 in human joint tissues. BMC Musculoskelet Disord. 2013;14:85. doi: 10.1186/1471-2474-14-85.
    1. Valdes AM, Evangelou E, Kerkhof HJ, Tamm A, Doherty SA, Kisand K, et al. The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance. Ann Rheum Dis. 2011;70(5):873–875. doi: 10.1136/ard.2010.134155.
    1. Sekimoto T, Ishii M, Emi M, Kurogi S, Funamoto T, Hamada H, et al. Segmental copy number loss in the region of Semaphorin 4D gene in patients with acetabular dysplasia. J Orthop Res. 2013;31(6):957–961. doi: 10.1002/jor.22310.
    1. McWilliams DF, Doherty SA, Jenkins WD, Maciewicz RA, Muir KR, Zhang W, et al. Mild acetabular dysplasia and risk of osteoarthritis of the hip: a case-control study. Ann Rheum Dis. 2010;69(10):1774–1778. doi: 10.1136/ard.2009.127076.
    1. Diaz-Prado S, Cicione C, Muinos-Lopez E, Hermida-Gomez T, Oreiro N, Fernandez-Lopez C, et al. Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord. 2012;13:144. doi: 10.1186/1471-2474-13-144.
    1. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One. 2008;3(11):e3740. doi: 10.1371/journal.pone.0003740.
    1. Ettinger WH, Davis MA, Neuhaus JM, Mallon KP. Long-term physical functioning in persons with knee osteoarthritis from NHANES. I: effects of comorbid medical conditions. J Clin Epidemiol. 1994;47(7):809–815. doi: 10.1016/0895-4356(94)90178-3.
    1. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255–263. doi: 10.1093/gerona/59.3.M255.
    1. Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W, et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci. 2013;68(1):62–67. doi: 10.1093/gerona/gls119.
    1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156. doi: 10.1093/gerona/56.3.M146.
    1. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–495. doi: 10.1503/cmaj.050051.
    1. Santos-Eggimann B, Cuenoud P, Spagnoli J, Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci. 2009;64(6):675–681. doi: 10.1093/gerona/glp012.
    1. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–762. doi: 10.1016/S0140-6736(12)62167-9.
    1. Sourial N, Bergman H, Karunananthan S, Wolfson C, Payette H, Gutierrez-Robledo LM, et al. Implementing frailty into clinical practice: a cautionary tale. J Gerontol A Biol Sci Med Sci. 2013;68(12):1505–1511. doi: 10.1093/gerona/glt053.
    1. Cesari M. The European Union Geriatric Medicine Society (EUGMS) working group on “frailty in older persons”. J Frailty Aging 2013;118–20.
    1. Vellas B, Cestac P, Moley JE. Implementing frailty into clinical practice: we cannot wait. J Nutr Health Aging. 2012;16(7):599–600. doi: 10.1007/s12603-012-0096-y.
    1. Wise BL, Parimi N, Zhang Y, Cawthon PM, Barrett-Connor E, Ensrud KE, et al. Frailty and hip osteoarthritis in men in the MrOS cohort. J Gerontol A Biol Sci Med Sci. 2014;69(5):602–608. doi: 10.1093/gerona/glt126.
    1. Hoops ML, Rosenblatt NJ, Hurt CP, Crenshaw J, Grabiner MD. Does lower extremity osteoarthritis exacerbate risk factors for falls in older adults? Womens Health (Lond Engl) 2012;8(6):685–696. doi: 10.2217/whe.12.53.
    1. Sharma L, Pai YC, Holtkamp K, Rymer WZ. Is knee joint proprioception worse in the arthritic knee versus the unaffected knee in unilateral knee osteoarthritis? Arthritis Rheum. 1997;40(8):1518–1525. doi: 10.1002/art.1780400821.
    1. Edwards MH, van der Pas S, Denkinger MD, Parsons C, Jameson KA, Schaap L, et al. Relationships between physical performance and knee and hip osteoarthritis: findings from the European Project on Osteoarthritis (EPOSA) Age Ageing. 2014;43(6):806–813. doi: 10.1093/ageing/afu068.
    1. Cacciatore F, Della-Morte D, Basile C, Mazzella F, Mastrobuoni C, Salsano E, et al. Long-term mortality in frail elderly subjects with osteoarthritis. Rheumatology (Oxford) 2014;53(2):293–299. doi: 10.1093/rheumatology/ket348.
    1. Pilotto A, Ferrucci L, Franceschi M, D’Ambrosio LP, Scarcelli C, Cascavilla L, et al. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res. 2008;11(1):151–161. doi: 10.1089/rej.2007.0569.
    1. Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC. Osteoarthritis: a case for personalized health care? Osteoarthr Cartil. 2014;22(1):7–16. doi: 10.1016/j.joca.2013.10.018.
    1. Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659–1664. doi: 10.1136/annrheumdis-2013-203355.
    1. Dougados M, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status. Ann Rheum Dis. 1996;55(6):356–362. doi: 10.1136/ard.55.6.356.
    1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355–369. doi: 10.1016/j.cger.2010.03.001.
    1. McWilliams DF, Leeb BF, Muthuri SG, Doherty M, Zhang W. Occupational risk factors for osteoarthritis of the knee: a meta-analysis. Osteoarthr Cartil. 2011;19(7):829–839. doi: 10.1016/j.joca.2011.02.016.
    1. van Dijk GM, Veenhof C, Spreeuwenberg P, Coene N, Burger BJ, van Schaardenburg SD, et al. Prognosis of limitations in activities in osteoarthritis of the hip or knee: a 3-year cohort study. Arch Phys Med Rehabil. 2010;91(1):58–66. doi: 10.1016/j.apmr.2009.08.147.
    1. Wluka AE, Cicuttini FM, Spector TD. Menopause, oestrogens and arthritis. Maturitas. 2000;35(3):183–199. doi: 10.1016/S0378-5122(00)00118-3.
    1. Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Evidence of a systemic predisposition to chondrocalcinosis and association between chondrocalcinosis and osteoarthritis at distant joints: a cross-sectional study. Arthritis Care Res (Hoboken) 2013;65(7):1052–1058. doi: 10.1002/acr.21952.
    1. Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum. 2000;43(5):995–1000. doi: 10.1002/1529-0131(200005)43:5<995::AID-ANR6>;2-1.
    1. Roos H, Lauren M, Adalberth T, Roos EM, Jonsson K, Lohmander LS. Knee osteoarthritis after meniscectomy: prevalence of radiographic changes after twenty-one years, compared with matched controls. Arthritis Rheum. 1998;41(4):687–693. doi: 10.1002/1529-0131(199804)41:4<687::AID-ART16>;2-2.
    1. Cooper C, Inskip H, Croft P, Campbell L, Smith G, McLaren M, et al. Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity. Am J Epidemiol. 1998;147(6):516–522. doi: 10.1093/oxfordjournals.aje.a009482.
    1. Richmond SA, Fukuchi RK, Ezzat A, Schneider K, Schneider G, Emery CA. Are joint injury, sport activity, physical activity, obesity, or occupational activities predictors for osteoarthritis? A systematic review. J Orthop Sports Phys Ther. 2013;43(8):B515–B519. doi: 10.2519/jospt.2013.4796.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다